An observational study in Depression and Trauma, Psychological, sponsored by Mclean Hospital. Recruiting at 1 site in United States. Open to female participants aged 20 Years to 32 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Mclean Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Depression by Mclean Hospital — 8 open to participants now, 10 under way, none of them phase 3. Depression · Mclean Hospital.
Among the 41 studies in Depression by Mclean Hospital, this one is the 3rd largest by planned enrollment of the 10 observational ones that give a count, is one of 4 that started in 2021, is one of 10 observational ones, and was the 31st registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →8 of the 41 studies in Depression by Mclean Hospital are open now, in 1 country. Recruiting first, the newest first:
Mclean Hospital · Sites in United States
Ages 18+ · Healthy volunteers
Mclean Hospital · Sites in United States
Ages 18+
Mclean Hospital · Sites in United States
Ages 18+
Mclean Hospital · Sites in United States
Ages 13–15 · Women only · Healthy volunteers
Mclean Hospital · Sites in United States
Ages 18–80
By country, each count listing its studies:
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 20 Years to 32 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 6 · Phase 3 2
First in 2004; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is close to the median of 175 across 1,261 observational studies indexed under Depression.
Median enrollment 68 across the 31 interventional studies, 112 across the 10 observational. Of the 28 that completed or were terminated, 11 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
Mclean Hospital is the lead sponsor of 185 studies on the registry; 31 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 12 (80%) have results posted.
6 of the studies in Depression by Mclean Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07868627Mclean HospitalNovel and Conventional Interventions for Cognitive and Emotional Flexibility in Patient Trauma | 2026-12-01 |
| NCT06876129Mclean HospitalPharmacologic Augmentation of TMS for Depression With D-serine | 2026-12-26 |
| NCT07785102Mclean HospitalSingle Day of Ultra-accelerated TMS With a Single Dose of NRX-101 | 2026-12-31 |
| NCT04325529Mclean HospitalPharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Study 1.2 (Stress Manipulation) | 2027-04-30 |
| NCT04713722Mclean HospitalEarly Life Stress and Depression: Molecular and Functional Imaging | 2027-04-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 41 studies in Depression by Mclean Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Severe childhood adversity accounts for a large portion of psychiatric illness, and an increased risk for major depressive disorder (MDD). For some individuals, childhood adversity has negative psychological and medical consequences; others preserve mental and physical health despite such experiences (they are resilient). In spite of this, little is known about the neurobiological mechanisms related to childhood adversity, especially oxidative stress abnormalities in the brain. To fill this gap, this study combines functional, structural, and molecular imaging approaches to examine the role of oxidative stress abnormalities related to childhood adversity.
Epidemiological studies have shown that severe childhood adversity explains 32-44% of psychiatric disorders, and is associated with 4.6-fold risk for MDD later in life. In spite of these epidemiological data, the neurobiological underpinnings associated with maladaptive sequelae of severe childhood adversity as well as resilience remain largely unknown.
Preclinical research suggests that early adversity leads to (1) structural abnormalities in brain regions critically implicated in stress regulation; (2) increased oxidative stress; and (3) glutamatergic abnormalities. The current research protocol is designed to prospectively test the contributions of these abnormalities in individuals exposed to severe childhood adversity.
Improving our understanding of neurobiological mechanisms associated with different childhood adversity outcomes is of paramount importance in order to (1) identify individuals at risk for psychopathology and maladaptive behavior, (2) prevent re-victimization, and (3) develop more targeted therapeutic interventions.
Healthy controls, those with depression (current or remitted), and those with depression and history of childhood adversity
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
subjects with current MDD who experienced childhood adversity
subjects with a history of MDD who experienced childhood adversity
subjects in a current episode of MDD, with no history of childhood adversity
healthy control subjects, with no history of childhood adversity
Immuno-oxidative abnormalities
Redox ratio and glutamate metabolites in the prefrontal cortex
Time frame: Baseline
Blood oxygen level dependent (BOLD) activation
Prefrontal cortex activation during a reward task
Time frame: Baseline
Blood oxygen level dependent (BOLD) activation in emotional processing
Prefrontal cortex activation during an emotional processing task
Time frame: Baseline
Peripheral inflammation
Stress-related pro-inflammatory transcription control pathways
Time frame: Baseline
Started Feb 2021 (actual). Primary completion is estimated for Apr 2027, 74 months after the start.
Of 463 non-industry observational studies under Depression, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 63. This study's planned 74 months is above that.
Counting every sponsor, half of 496 studies reached it within 32 months; a quarter within 13 and three quarters within 61.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Jun 2026 → Apr 2027 and completion Jun 2026 → Apr 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.